Neurodegenerative Diseases Progression Markers (MARKERS-NDD)

Sponsor
Casa di Cura San Raffaele Cassino
Study ID
NCT06596746
Status
Recruiting
Apply to this trial

Conditions

  • Alzheimer Disease
  • Amyotrophic Lateral Sclerosis
  • Atypical Parkinsonism
  • Cognitive Impairment
  • Corticobasal Degeneration
  • Dementia
  • Frontotemporal Lobar Degeneration
  • Iron Overload
  • Lewy Body Disease
  • Movement Disorders
  • Multiple System Atrophy
  • Neurodegeneration With Brain Iron Accumulation (NBIA)
  • Neurodegenerative Diseases
  • Parkinson Disease
  • Supranuclear Palsy, Progressive
  • Synucleinopathies
  • TDP-43 Proteinopathies
  • Tauopathies

Eligibility Criteria

Sex
ALL
Age
10 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Observation — OTHER
    In MARKERS-NDD up to 600 participants will be enrolled and followed longitudinally once identified, over the course of 1-10 years

Study Details

MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.

Key Dates

First listed
Sep 19, 2024
Start date
Sep 9, 2024
Status verified
Sep 2024
Primary completion
Sep 9, 2034
Completion
Sep 9, 2034

Study Design

Enrollment
600 participants (estimated)

Arms

  • Arm: Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders
  • Arm: Patients affected by cognitive impairment (CI) and dementia

Primary Outcome Measure

To monitor and predict the course of neurodegenerative diseases through the study of clinical markers and the creation of AI-models [ Time Frame: Baseline to 120 months ]

Central Contacts

Find similar trials

Nationwide
Alzheimer's disease trialsParkinson's disease trialsNeurology trialsDementia care trialsBrain disorders trialsGeriatrics trials

Related Studies